ACUTE LEUKEMIA CANTERA

FRANCECO BOCCALATTE
NYU Langone Medical Center

CIRINO BOTTA
Università degli Studi di Palermo

Cirino Botta, MD, PhD, born in Battipaglia (SA) on 10/08/1985, is Assistant Professor of Hematology at the University of Palermo. He graduated cum laude in Medicine and Surgery in 2010 at the University of Siena, next moved to the University of Catanzaro from 2011 to 2018 where he achieved the specialty in Medical Oncology and the PhD in Translational Oncology devoting his research to immunotherapy and multiple myeloma. From May 2018 to May 2019 he worked as a post-doc at the “Clinica Universidad de Navarra” in Pamplona, Spain, in the group led by Dr. Bruno Paiva and Prof. Jesus San Miguel. Next, From May 2019 to April 2021 he joined as staff physician and senior researcher, the Hematology Unit of the “Annunziata” Hospital of Cosenza, where he was in charge for the management of multiple myeloma patients. In December 2020 he won a 5-years grant from the Italian Association for Cancer Research (AIRC, MFAG) to investigate the role of immune microenvironment (at single cell level) and microbiota in the disease evolution from MGUS to smoldering to active myeloma. Since April 2021, he joined the Hematology Unit of the University of Palermo as an Assistant Professor (Tenure track) of hematology, where he is involved in the management of multiple myeloma patients.

ALESSANDRO FIORENTINI
Ospedali Riuniti di Ancona

MARIA CHIARA FONTANA
Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST

MARTINA GHETTI
Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST

ERICA IMBROGNO
Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST

ADRIÁN MOSQUERA ORGUEIRA
Clinical Hospital of Santiago de Compostela

I am a 31-year old hematologist from Spain working in the University Hospital of Santiago de Compostela. I combine my medical duties with my PhD studies and with my research line in lymphoid malignancies. In particular, I am centered in genomics of hematological tumors, bioinformatics analysis and artificial intelligence applications to cancer treatment and survival prediction. Furthermore, I also have experience in CAR-T therapy, and I participate in research projects to foster CAR-T therapy development and its clinical implantation in Spain.

VASILE MUSTEATA
State University of Medicine and Pharmacy “N. Testemitanu”, Chisinau, Republic of Moldova

Born on 21 June 1972, in the city of Chisinau. In 1989 he had graduated with medal decoration from the secondary school of the city of Chisinau, and then in 1995 – with excellence from the General Medicine faculty of the State University of Medicine and Pharmacy „Nicolae Testemitanu”. In 1995 – 1997 he had accomplished the postgraduate studies through the clinical internship, followed by the postgraduate studies via doctorate in 1997 – 2000 at the Chair of Hematology, Oncology and Military Therapy of the State University of Medicine and Pharmacy „Nicolae Testemitanu”. In 2002 Dr. Vasile Musteata supported the thesis “Clinical aspects, diagnosis and treatment of primary non-Hodgkin’s lymphomas of the spleen” within the frame of the Specialized Scientific Council of the PMSI Institute of Oncology. In 2009 – 2011 he had performed the postgraduate studies through the master program at the School of Public Health Management of the State University of Medicine and Pharmacy „Nicolae Testemitanu”. Since 1998 he has been holding concomitantly the external appointment of the attending physician at the Institute of Oncology. Since 2000 he has been activating in the position of the university assistant at the Chair of Hematology, Oncology and Military Therapy. Associate professor (2009). Since 2012 he has been holding the appointment of the studies chief at the chair and discipline. In 2011 he had participated at the international training “Perfections in Management of Public Health” under the auspices of Ecole de Santé Publique – Groupe Hospitalier Saint Augustin (Malestroit, France) and the State University of Medicine and Pharmacy „Nicolae Testemitanu”, and in 2012 – in the ERSAP Preceptorship Program in the field of hematologic malignancies at the MD Anderson Cancer Center (The University of Texas, Houston, USA). In 2002 – 2012 he had held an appointment of the European Society of Medical Oncology (ESMO) national representative in the Republic of Moldova. Dr. Vasile Musteata is an author and co-author of more than 200 scientific publications, 3 methodical-didactic compendiums, 6 national clinical protocols, one book and one invention. The main scientific directions are leukemias and non-Hodgkin lymphomas. In 2006 he was decorated with the Award for Youth in the domain of Sciences, Technology, Literature and Arts, on behalf of the Government of the Republic of Moldova.

JACOPO NANNI
Ospedale S.Orsola, Bologna

ANTONELLA PADELLA 
Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST

SIMONA PIEMONTESE
European Group for Blood and Marrow Transplantation (EBMT) Hopital Saint Antoine

VITTORIA RAIMONDI
Istituto Oncologico Veneto IOV IRCCS

Vittoria Raimondi obtained her M. Sc. degree in Health Biology in 2012 with final grade 110/110 cum laude and her Ph.D. in Biomedicine in 2017, both at University of Padova. In these periods, she studied novel approaches to counteract viral infections caused by the retroviral agents HIV-1 and HTLV-1. In particular, she exploited lentiviral vectors for the delivery of siRNAs directed against viral and host factors involved in HIV-1 infection and deepened the role of miR-34a in the development of HTLV-1-induced ATLL. Currently she is working in the laboratory of Prof. Vincenzo Ciminale at the Istituto Oncologico Veneto IOV-IRCCS. Her research activity is focused on the development of novel pharmacological strategies to target relapsed/refractory hematological malignancies, in particular DLBCL and AML, by modulating redox homeostasis and autophagy. She filed two Italian and two International patents describing new pharmacological combinations to sensitize DLBCL, AML and T-ALL to drug-induced apoptosis. She is member of Società Italiana di Cancerologia (SIC), Italian Society of Hematologic Oncology (SOHO Italy), and Ambassador of the European Association for Cancer Research (EACR). She also held teaching activities in Pharmacology and Microbiology at University of Padova.

CHIARA SARTOR
Università di Bologna

2012 Dal mese di Settembre, attività di medico frequentatore presso l’Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Policlinico “Sant’Orsola-Malpighi”, Bologna.
2013 Dal mese di Luglio, attività clinica di medico in formazione specialistica in Ematologia presso l’Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Policlinico “Sant’Orsola-Malpighi”, Bologna.
2018 Dal mese di Ottobre, assegnista di ricerca con attivazione clinico-assistenziale per il settore MED/15 – Malattie del Sangue, presso l’Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Policlinico “Sant’Orsola-Malpighi”, Bologna, con afferenza al Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale.
2018 Dal mese di Novembre, dottorando di ricerca con attivazione clinico-assistenziale in “Oncologia, Ematologia e Patologia”, curriculum “Ematologia clinica e sperimentale”, presso l’Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Policlinico “Sant’Orsola-Malpighi”, Bologna.

MICOL SILIC-BENUSSI
Istituto Oncologico Veneto IOV IRCCS

Dr Micol Silic-Benussi received her Laurea in Biological Sciences (5-year degree equivalent to BSc and Master degree) from the University of Padova, received her PhD in Oncology and Surgical Sciences from the University of Padova in 2006. After the PhD. Dr Silic-Benussi spent eight months as a visiting scientist in the laboratory of Dr M.D. Franchini G.at NIH in Bethesda, Maryland (USA) before joining the laboratory of Prof. Ciminale in Padova as a postdoc. Dr Silic-Benussi is now a researcher at Istituto Oncologico Veneto-IRCCS. Dr Silic-Benussi research interests are focused on understanding signal transduction pathways controlled by reactive oxygen species (ROS). ROS’s modulation is essential in the context of the control of cell turnover (proliferation and/or apoptosis). Recently she concentrated on studying the crosstalk between the mTOR pathway and ROS homeostasis in T-ALL cells to understand the mechanism by which T-ALL cells, but not normal T-cells, die in response to mTORC1 inhibition. The results obtained will allow stratifying GC-resistant T-ALL patients to select those more likely to benefit from inhibitors of TORC1.

GIORGIA SIMONETTI
Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST